Tag: subarachnoid haemorrhage
Cerevasc highlights eShunt study presentations from ABC WIN Seminar
Cerevasc has announced that data from clinical studies in the USA and Argentina examining the use of its eShunt system to treat communicating hydrocephalus were presented at...
‘Surprising’ regional variations in subarachnoid haemorrhage care revealed by Finnish study
A study recently published in the journal Neurology investigated whether there are discrepancies in the prognosis of subarachnoid haemorrhage (SAH) patients between the university hospital...
US Brain Aneurysm Foundation announces 2023 research grants
The Brain Aneurysm Foundation (BAF) has announced the recipients of its 2023 research grants, providing support to academic researchers studying the underlying biology of aneurysms or...
Cerevasc announces presentation of initial eShunt data at ESMINT 2023
Cerevasc has today announced that findings from a clinical study examining the use of its eShunt system to treat communicating hydrocephalus were recently presented...
Brain Aneurysm Foundation launches ‘Stop the Pop’ campaign
The Brain Aneurysm Foundation (BAF) has announced the launch of ‘Stop the Pop’—a new campaign intended to increase awareness of the prevalence and impact...
US and Chinese experts introduce new aneurysmal subarachnoid haemorrhage guidelines
Expert groups from the USA and China have separately introduced new guidelines relating to the management of aneurysmal subarachnoid haemorrhage (aSAH). The updated guidelines—spearheaded...
Intraoperative adverse events found to impede favourable outcomes in microsurgical aneurysm...
A nationwide study drawing on data from Swedish patients has indicated that—while the majority of ruptured intracranial aneurysm patients treated with microsurgery experienced favourable...
Five-year project sets out to improve brain aneurysm treatments with customisable...
A team from the University of Oklahoma (Norman, USA) has embarked on a five-year research project with the intention of designing a device that...
CereVasc announces US FDA approval for second IDE study of eShunt...
CereVasc announced today that the US Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to initiate a pilot trial...
Current literature suggests promise held by electrical stimulation therapies for cerebral...
Electrical stimulation technologies, and in particular spinal cord stimulation (SCS) and sphenopalatine ganglion stimulation, offer a promising adjunct to existing therapies for cerebral vasospasm...
